Novartis AG said one-year results of its drug secukinumab show it is effective in treating patients with ankylosing spondylitis (AS), a debilitating joint condition of the spine.


The Basel-based drugmaker said it will present detailed results from the study at a rheumatism conference in Rome this week.




(Reporting by Katharina Bart; Editing by Shri Navaratnam)

Source: Reuters